Manuel Merlos

List of Publications by Year
in descending order

121 papers	4,511 citations	109264 35 h-index	123376 61 g-index
123 all docs	123 docs citations	123 times ranked	5379 citing authors

#	Article	IF	Citations
1	Comprehensive Preclinical Assessment of Sensory, Functional, Motivational-Affective, and Neurochemical Outcomes in Neuropathic Pain: The Case of the Sigma-1 Receptor. ACS Pharmacology and Translational Science, 2022, 5, 240-254.	2.5	5
2	Identification of Sodium Transients Through NaV1.5 Channels as Regulators of Differentiation in Immortalized Dorsal Root Ganglia Neurons. Frontiers in Cellular Neuroscience, 2022, 16, 816325.	1.8	1
3	Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition. Scientific Reports, 2022, 12, .	1.6	12
4	Development of a novel in vitro assay to screen for neuroprotective drugs against iatrogenic neurite shortening. PLoS ONE, 2021, 16, e0248139.	1.1	3
5	Identification of Novel Regulators of Zalcitabine-Induced Neuropathic Pain. ACS Chemical Neuroscience, 2021, 12, 2619-2628.	1.7	3
6	Outsideâ€in regulation of the readily releasable pool of synaptic vesicles by Î±2Îˆâ€1. FASEB Journal, 2020, 34, 1362-1377.	0.2	7
7	Discovery of EST73502, a Dual Î¼-Opioid Receptor Agonist and Ïƒ₁ Receptor Antagonist Clinical Candidate for the Treatment of Pain. Journal of Medicinal Chemistry, 2020, 63, 15508-15526.	2.9	23
8	The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception. Molecular Brain, 2020, 13, 150.	1.3	13
9	Urinary bladder sigma-1 receptors: A new target for cystitis treatment. Pharmacological Research, 2020, 155, 104724.	3.1	10
10	Sigmaâ€1 receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain. British Journal of Pharmacology, 2019, 176, 3939-3955.	2.7	26
11	Ligands Exert Biased Activity to Regulate Sigma 1 Receptor Interactions With Cationic TRPA1, TRPV1, and TRPM8 Channels. Frontiers in Pharmacology, 2019, 10, 634.	1.6	18
12	Blockade of the Sigma-1 Receptor Relieves Cognitive and Emotional Impairments Associated to Chronic Osteoarthritis Pain. Frontiers in Pharmacology, 2019, 10, 468.	1.6	29
13	Supraspinal and Peripheral, but Not Intrathecal, Ïƒ1R Blockade by S1RA Enhances Morphine Antinociception. Frontiers in Pharmacology, 2019, 10, 422.	1.6	8
14	Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. Expert Opinion on Investigational Drugs, 2019, 28, 399-409.	1.9	26
15	Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice. Frontiers in Pharmacology, 2019, 10, 222.	1.6	25
16	A New Model of Sensorial Neuron-Like Cells for HTS of Novel Analgesics for Neuropathic Pain. SLAS Discovery, 2019, 24, 158-168.	1.4	10
17	The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9. Molecular Neurobiology, 2018, 55, 4940-4951.	1.9	27
18	May a sigmaâ€1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats?. European Journal of Pain, 2018, 23, 603-620.	1.4	6

#	Article	IF	Citations
19	Administration of a co-crystal of tramadol and celecoxib in a 1:1 molecular ratio produces synergistic antinociceptive effects in a postoperative pain model in rats. European Journal of Pharmacology, 2018, 833, 370-378.	1.7	26
20	Sigma-1 Receptor and Pain. Handbook of Experimental Pharmacology, 2017, 244, 131-161.	0.9	46
21	Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain. Advances in Experimental Medicine and Biology, 2017, 964, 85-107.	0.8	39
22	Pharmacological sensitivity of reflexive and nonreflexive outcomes as a correlate of the sensory and affective responses to visceral pain in mice. Scientific Reports, 2017, 7, 13428.	1.6	10
23	A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses. Scientific Reports, 2017, 7, 15389.	1.6	24
24	Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats. European Journal of Pain, 2017, 21, 61-72.	1.4	21
25	The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats. Scientific Reports, 2016, 6, 24591.	1.6	61
26	Antinociception by Sigma-1 Receptor Antagonists. Advances in Pharmacology, 2016, 75, 179-215.	1.2	40
27	Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget, 2016, 7, 55840-55862.	0.8	66
28	Changes in saccharin preference behavior as a primary outcome to evaluate pain and analgesia in acetic acid-induced visceral pain in mice. Journal of Pain Research, 2015, 8, 663.	0.8	13
29	Investigational sigma-1 receptor antagonists for the treatment of pain. Expert Opinion on Investigational Drugs, 2015, 24, 883-896.	1.9	48
30	The Ïƒ1 Receptor Engages the Redox-Regulated HINT1 Protein to Bring Opioid Analgesia Under NMDA Receptor Negative Control. Antioxidants and Redox Signaling, 2015, 22, 799-818.	2.5	71
31	Effects of centrally acting analgesics on spinal segmental reflexes and windâ€up. European Journal of Pain, 2015, 19, 1012-1020.	1.4	19
32	Effects of the selective sigmaâ€1 receptor antagonist S1<scp>RA</scp> on formalinâ€induced pain behavior and neurotransmitter release in the spinal cord in rats. Journal of Neurochemistry, 2014, 129, 484-494.	2.1	34
33	S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freundâ€™s adjuvant models in mice. Behavioural Pharmacology, 2014, 25, 226-235.	0.8	55
34	Liquid fructose down-regulates liver insulin receptor substrate 2 and gluconeogenic enzymes by modifying nutrient sensing factors in rats. Journal of Nutritional Biochemistry, 2014, 25, 250-258.	1.9	36
35	Liquid fructose downregulates Sirt1 expression and activity and impairs the oxidation of fatty acids in rat and human liver cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 514-524.	1.2	37
36	Modulation of PeripheralÎ¼-Opioid Analgesia byÏƒ₁Receptors. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 32-45.	1.3	74

#	Article	IF	Citations
37	Evaluation of Responsive Gene Expression as a Sensitive and Specific Biomarker in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 221-229.	0.9	19
38	Sigma 1 receptor: A new therapeutic target for pain. European Journal of Pharmacology, 2013, 716, 78-93.	1.7	117
39	Synthesis and Biological Evaluation of a New Series of Hexahydro-2H-pyrano[3,2-c]quinolines as Novel Selective Ïƒ₁ Receptor Ligands. Journal of Medicinal Chemistry, 2013, 56, 3656-3665.	2.9	34
40	Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects. European Journal of Pharmacology, 2013, 711, 63-72.	1.7	76
41	Is the H4 receptor a new drug target for allergies and asthma. Frontiers in Bioscience - Elite, 2013, E5, 178-187.	0.9	32
42	Ïƒ1Receptors Are Involved in the Visceral Pain Induced by Intracolonic Administration of Capsaicin in Mice. Anesthesiology, 2013, 118, 691-700.	1.3	42
43	Evaluation of Formalin-Induced Pain Behavior and Glutamate Release in the Spinal Dorsal Horn Using In Vivo Microdialysis in Conscious Rats. Journal of Pharmacological Sciences, 2012, 120, 129-132.	1.1	16
44	Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of Ïƒ₁ Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA,) Tj ETQq0 0 0 rgBT /Overlock 10	2.9	125
45	Pharmacological properties of S1RA, a new sigmaâ€1 receptor antagonist that inhibits neuropathic pain and activityâ€induced spinal sensitization. British Journal of Pharmacology, 2012, 166, 2289-2306.	2.7	159
46	Metabolic Alterations and Increased Liver mTOR Expression Precede the Development of Autoimmune Disease in a Murine Model of Lupus Erythematosus. PLoS ONE, 2012, 7, e51118.	1.1	26
47	The intestinal antiâ€inflammatory effect of dersalazine sodium is related to a downâ€regulation in ILâ€17 production in experimental models of rodent colitis. British Journal of Pharmacology, 2012, 165, 729-740.	2.7	31
48	PPARÎ²/Î´ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 59-67.	1.2	66
49	Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicology and Applied Pharmacology, 2011, 251, 32-40.	1.3	54
50	Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1254-1260.	1.9	17
51	UR-60427, a novel H4 receptor-inverse agonist that shows good efficacy in a rat asthma model. Inflammation Research, 2010, 59, 199-200.	1.6	7
52	The Role of Peroxisome Proliferator-Activated Receptor Î²/Î´ on the Inflammatory Basis of Metabolic Disease. PPAR Research, 2010, 2010, 1-11.	1.1	22
53	Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology, 2009, 49, 106-115.	3.6	58
54	The New Salicylate Derivative UR-1505 Modulates the Th2/Humoral Response in a Dextran Sodium Sulphate Model of Colitis That Resembles Ulcerative Colitis. Journal of Pharmacological Sciences, 2009, 109, 315-318.	1.1	6

#	Article	IF	Citations
55	Antihistaminic effects of rupatadine and PKPD modelling. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 107-116.	0.6	12
56	UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis. Inflammatory Bowel Diseases, 2008, 14, 888-897.	0.9	9
57	Disturbances in metabolic, transport and structural genes in experimental colonic inflammation in the rat: a longitudinal genomic analysis. BMC Genomics, 2008, 9, 490.	1.2	27
58	Activation of Peroxisome Proliferatorâ€“Activated Receptor Î²/Î´ Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-ÎºB Activity via Extracellular Signalâ€“Related Kinase 1/2. Diabetes, 2008, 57, 2149-2157.	0.3	108
59	Atorvastatin inhibits GSK-3Î² phosphorylation by cardiac hypertrophic stimuli. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 26-35.	1.2	17
60	Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Clinical Therapeutics, 2008, 30, 1639-1650.	1.1	22
61	Oleate Reverses Palmitate-induced Insulin Resistance and Inflammation in Skeletal Muscle Cells. Journal of Biological Chemistry, 2008, 283, 11107-11116.	1.6	285
62	UR-1505, a New Salicylate, Blocks T Cell Activation through Nuclear Factor of Activated T Cells. Molecular Pharmacology, 2007, 72, 269-279.	1.0	18
63	Peroxisome Proliferator-Activated Receptor Â Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1326-1336.	1.7	26
64	Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: A single-dose, randomized, open-label, two-way crossover study. Clinical Therapeutics, 2007, 29, 900-908.	1.1	29
65	The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochemical Pharmacology, 2007, 74, 1496-1506.	2.0	15
66	PGC-1ss Down-Regulation Is Associated With Reduced ERRÂ Activity and MCAD Expression in Skeletal Muscle of Senescence-Accelerated Mice. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 773-780.	1.7	32
67	A small molecule, orally active, Î± 4 Î² 1 /Î± 4 Î² 7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. British Journal of Pharmacology, 2006, 147, 661-670.	2.7	29
68	Palmitate Induces Tumor Necrosis Factor-Î± Expression in C2C12 Skeletal Muscle Cells by a Mechanism Involving Protein Kinase C and Nuclear Factor-ÎºB Activation. Endocrinology, 2006, 147, 552-561.	1.4	155
69	Inhibition of Cardiac Hypertrophy by Triflusal (4-Trifluoromethyl Derivative of Salicylate) and Its Active Metabolite. Molecular Pharmacology, 2006, 69, 1174-1181.	1.0	6
70	Palmitate-Mediated Downregulation of Peroxisome Proliferator-Activated Receptor-Â Coactivator 1Â in Skeletal Muscle Cells Involves MEK1/2 and Nuclear Factor-ÂB Activation. Diabetes, 2006, 55, 2779-2787.	0.3	134
71	Atorvastatin prevents peroxisome proliferator-activated receptor Î³ coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1736, 120-127.	1.2	23
72	New Water-Soluble Sulfonylphosphoramidic Acid Derivatives of the COX-2 Selective Inhibitor Cimicoxib. A Novel Approach to Sulfonamide Prodrugs. Journal of Medicinal Chemistry, 2004, 47, 5579-5582.	2.9	27

#	Article	IF	Citations
73	The Intestinal Anti-inflammatory Activity of UR-12746S on Reactivated Experimental Colitis Is Mediated Through Downregulation of Cytokine Production. Inflammatory Bowel Diseases, 2003, 9, 363-371.	0.9	28
74	Synthesis and Structureâ"Activity Relationship of a New Series of COX-2 Selective Inhibitors:â€‰ 1,5-Diarylimidazoles. Journal of Medicinal Chemistry, 2003, 46, 3463-3475.	2.9	128
75	Down-regulation of acyl-CoA oxidase gene expression and increased NF-ÎºB activity in etomoxir-induced cardiac hypertrophy. Journal of Lipid Research, 2003, 44, 388-398.	2.0	39
76	Down-Regulation of Acyl-CoA Oxidase Gene Expression in Heart of Troglitazone-Treated Mice through a Mechanism Involving Chicken Ovalbumin Upstream Promoter Transcription Factor II. Molecular Pharmacology, 2003, 64, 764-772.	1.0	21
77	Rupatadine: A new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Drugs of Today, 2003, 39, 451.	2.4	77
78	Novel Azo Derivatives as Prodrugs of 5-Aminosalicylic Acid and Amino Derivatives with Potent Platelet Activating Factor Antagonist Activity. Journal of Medicinal Chemistry, 2001, 44, 3001-3013.	2.9	33
79	Alternative Binding Assay of GP IIb/IIIa Antagonists With a Nonradioactive Labeling Method of Platelets. Thrombosis Research, 2001, 102, 247-253.	0.8	3
80	Protective effect of URâ€‰12670 on chronic nephropathy induced by warm ischaemia in ageing uninephrectomized rats. Nephrology Dialysis Transplantation, 2001, 16, 735-741.	0.4	12
81	Synthesis and SAR of a New Series of COX-2-Selective Inhibitors:Â Pyrazolo[1,5-a]pyrimidines. Journal of Medicinal Chemistry, 2001, 44, 350-361.	2.9	158
82	Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor Îº B-dependent transcription in human astrocytoma cells. British Journal of Pharmacology, 2001, 132, 547-555.	2.7	13
83	Walnut-enriched diet increases the association of LDL from hypercholesterolemic men with human HepG2 cells. Journal of Lipid Research, 2001, 42, 2069-2076.	2.0	46
84	Substituting Walnuts for Monounsaturated Fat Improves the Serum Lipid Profile of Hypercholesterolemic Men and Women. Annals of Internal Medicine, 2000, 132, 538.	2.0	243
85	COLD ISCHEMIA IN THE ABSENCE OF ALLOREACTIVITY INDUCES CHRONIC TRANSPLANT NEPHROPATHY THROUGH A PROCESS MEDIATED BY THE PLATELET-ACTIVATING FACTOR1. Transplantation, 2000, 70, 1624-1631.	0.5	19
86	Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. British Journal of Pharmacology, 2000, 130, 1949-1959.	2.7	41
87	Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. Kidney International, 1999, 56, 1798-1808.	2.6	30
88	Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced byAscaris suum in hypersensitive dogs. Drug Development Research, 1998, 44, 49-55.	1.4	19
89	Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia. British Journal of Clinical Pharmacology, 1998, 45, 265-269.	1.1	12
90	Influence of Lipid Profile and Fatty Acid Composition on the Oxidation Behavior of Rat and Guinea Pig Low Density Lipoprotein. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1998, 119, 311-316.	0.7	9

#	Article	IF	Citations
91	New Azole Antifungals. 2. Synthesis and Antifungal Activity of Heterocyclecarboxamide Derivatives of 3-Amino-2-aryl-1-azolyl-2-butanol1. Journal of Medicinal Chemistry, 1998, 41, 1855-1868.	2.9	43
92	New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(3H)-quinazolinones1,2. Journal of Medicinal Chemistry, 1998, 41, 1869-1882.	2.9	203
93	Effect of endotoxin and platelet-activating factor on rat vascular permeability: role of vasoactive mediators. Journal of Lipid Mediators and Cell Signalling, 1997, 17, 31-45.	1.0	5
94	Effects of URâ€12633, a new antagonist of plateletâ€activating factor, in rodent models of endotoxic shock. British Journal of Pharmacology, 1996, 118, 1223-1231.	2.7	17
95	Decreased susceptibility to copperâ€induced oxidation of ratâ€lipoproteins after fibrate treatment: influence of fatty acid composition. British Journal of Pharmacology, 1996, 117, 1155-1162.	2.7	34
96	Design, Synthesis, and Structureâ^'Activity Relationship Studies of Novel 1-[(1-Acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine Derivatives as Potent, Orally Active Plateletâ^'Activating Factor Antagonists. Journal of Medicinal Chemistry, 1996, 39, 487-493.	2.9	21
97	Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: A comparison of a Microplate Filtration System and a standard method. Journal of Pharmacological and Toxicological Methods, 1996, 36, 53-62.	0.3	5
98	Topical anti-inflammatory properties of flutrimazole, a new imidazole antifungal agent. Inflammation Research, 1996, 45, 20-25.	1.6	14
99	Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: Comparison with antihistamines and PAF antagonists. Drug Development Research, 1996, 39, 12-18.	1.4	24
100	Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guineaâ€pigs. British Journal of Pharmacology, 1995, 116, 3337-3343.	2.7	12
101	Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. British Journal of Pharmacology, 1995, 116, 2067-2075.	2.7	14
102	Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation. British Journal of Pharmacology, 1995, 114, 1351-1358.	2.7	27
103	[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine. Journal of Medicinal Chemistry, 1994, 37, 2697-2703.	2.9	39
104	Relationship between plasma lipids and palmitoylâ€CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. British Journal of Pharmacology, 1994, 112, 551-556.	2.7	38
105	Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists. Journal of Medicinal Chemistry, 1993, 36, 2984-2997.	2.9	38
106	Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation. Biochemical Pharmacology, 1993, 46, 1515-1518.	2.0	8
107	Fibrates modify rat hepatic fatty acid chain elongation and desaturation in vitro. Biochemical Pharmacology, 1993, 46, 1791-1796.	2.0	13
108	Cytosolic lipogenic enzymes: Effect of fibric acid derivatives in vitro. Life Sciences, 1993, 52, 213-222.	2.0	9

#	Article	IF	Citations
109	Inhibition of rat liver microsomal fatty acid chain elongation by gemfibrozil in vitro. FEBS Letters, 1992, 300, 89-92.	1.3	12
110	(Pyridylcyanomethyl)piperazines as orally active PAF antagonists. Journal of Medicinal Chemistry, 1992, 35, 4118-4134.	2.9	10
111	4-Substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists. Journal of Medicinal Chemistry, 1992, 35, 676-683.	2.9	7
112	Differential inhibition of long-chain acyl-CoA hydrolases by hypolipidemic drugs in vitro. Biochemical Pharmacology, 1992, 43, 639-644.	2.0	12
113	Effects of PAFâ€antagonists in mouse ear oedema induced by several inflammatory agents. British Journal of Pharmacology, 1991, 104, 990-994.	2.7	37
114	Disubstituted tetrahydrofurans and dioxolanes as platelet activating factor (PAF) antagonists. Journal of Medicinal Chemistry, 1991, 34, 373-386.	2.9	15
115	Design of potent linear PAF antagonists. Journal of Medicinal Chemistry, 1991, 34, 3328-3334.	2.9	2
116	In vitro effect of clofibric acid derivatives on rat hepatic microsomal electron transport chains. Biochemical Pharmacology, 1991, 42, 2057-2060.	2.0	8
117	Flavonoids as inhibitors of rat liver cytosolic glutathione S-transferase. Experientia, 1991, 47, 616-619.	1.2	26
118	Structure-activity relationships in a series of xanthine derivatives with antibronchoconstrictory and bronchodilatory activities. European Journal of Medicinal Chemistry, 1990, 25, 653-658.	2.6	13
119	Comparative Study of the Effect of CV-6209, a Specific PAF-Antagonist, on Rat Paw Edema Caused by Different Phlogogen Agents. Pharmacology, 1990, 40, 211-217.	0.9	14
120	Bronchodilator xanthine derivative with potent in vitro and in vivo activity after oral, parenteral or by inhalation administration. European Journal of Pharmacology, 1990, 183, 2125-2126.	1.7	0
121	In vitro study of caffeic acid â€" bovine serum albumin interaction. European Journal of Drug Metabolism and Pharmacokinetics, 1988, 13, 11-14.	0.6	17